CLINICAL STUDIES PROF. DR. NOAH
| Zeitraum | Studie |
|---|---|
| 2016 – 2017 | AWB Dermalfiller SF-24, MPG(PI), 39 Patients |
| 2005 – 2006 | Phase 3 Scar healing, AMG (PI) |
| 2010 – 2012 | Phase 3 Facelift, MPG (PI) |
| 2010 | Experimentee lymphatic architectural , AMG (PI) |
| 2011 | Phase 3 Double Chin Study, MPG (PI) |
| 2012 – 2013 | Phase 3 Study Simultaneous treatment of upper facelines, AM |
| 2014 – 2015 | Phase II Treatment of hypertrophic Breast scar, AMG (PI) EudraCT-Nr.: 2012-004355-37 ,7 Patients |
| 2014 – 2020 | Phase IV Implantation of Orbix medical Breast lifting system, M |
| 2014 – 2015 | AWB Dermalfiller SF-16, MPG (PI) 8 patients |
| 2015 – 2016 | Phase 3 double blind Treatment of Clostridium Botulinum ToxiType A of Glabellar lines, AMG (PI) EudraCT-Nr: 2013-002321-34, 20 |
| 2015 – 2016 | Phase 3 Treatment of IncobotulinumtoxinA of upper face lines, AMG (PI) 9 Patients |
| 2015 – 2016 | Phase 3 open label Treatment with Clostridium Botulinum Toxin Type A of Glabellar lines, AMG (PI) EudraCT-Nr: 2014-003841-86, 23 Patients |
| 2015 – 2017 | AWB Treatment with Hyaluronic acid in chin and chaw, MPG (PI,) 8 Patie |
| 2016 – 2017 | Post market follow up Study with Dermalfiller of moderate and severe facial wrinkles/folds, MPG (PI), 8 Patients |
| 2018 – 2019 | Post market follow up Study with Dermalfiller to to confirm performance and safety of Belotero® Soft Lidocaine and Belotero® Intense Lidocaine in the treatment of nasolabial folds, perioral fine lines and/or for lip volume enhancement, MPG (Sub-I), 25 Patients |
| 2018 – 2019 | AWB of cell-free autologous Conditioned Serum in patients with skin elasticity loss different grades, MPG (PI) 26 Patients |
| 2019 – 2020 | Prospective, multicenter, parallel-group, evaluator-blind, randomized study to investigate the effectiveness and safety of MRZF111 in the treatment of décolleté wrinkles (MPG) (PI) 24 Patients |
| 2019 – 2022 | A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines (PI) (AMG) EudraCT-Nr.: 2014-005301-21 (PI) 14 Patients |
